Starling Oncology, Inc. (STLNW) company profile

The Oncology Institute, Inc. delivers outpatient medical and radiation oncology care alongside specialty pharmacy and clinical research services. The company provides treatments such as in-house infusion, radiation therapy, and blood product transfusions, operating through patient services, pharmacy distribution, and clinical trial management. It delivers care under fee-for-service arrangements and value-based risk contracts, including capitation and full delegation models where it assumes administrative functions such as utilization management and claims processing. Its customer base includes commercial and government healthcare payors, Medicare Advantage plans, Medicaid, managed care organizations, and adult cancer patients.

The company operates across 17 markets in five U.S. states: California, Arizona, Nevada, Florida, and Oregon. Its care network encompasses 65 physician-owned affiliated clinics with 116 providers, 81 managed contracted clinics, and 198 independent network providers, managing roughly 2.0 million patients under value-based agreements. The text states its operational presence across these states but does not specify a corporate headquarters location.

Summary of the business section of Starling Oncology's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Each unit has an offering price of $10.00 and consists of one share of Class A common stock and one-fourth of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we and TOI PCs collectively had approximately 641 employees, including approximately 116 oncologists and advanced practice providers.”